Jesús García Mata

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

Thomas Bachelot, Eva Ciruelos, Fabio Puglisi et al. · Annals of Oncology · 2019 · 113 citations · Full text

Medicine, Oncology, Pharmacology +17

Monotherapy versus combination therapy for sepsis due to multidrug-resistant Acinetobacter baumannii: analysis of a multicentre prospective cohort

Luis Eduardo López-Cortés, José Miguel Cisneros, Felipe Fernández-Cuenca et al. · Journal of Antimicrobial Chemotherapy · 2014 · 107 citations · Full text

Veterinary Medicine, Infectious Diseases, Pharmacotherapy +17

Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

David Miles, Eva Ciruelos, Fabio Puglisi et al. · Annals of Oncology · 2021 · 89 citations · Full text

Medicine, Oncology, Pharmacology +17

Real world data of nivolumab for previously treated non-small cell lung cancer patients: a Galician lung cancer group clinical experience

Ma Carmen Areses Manrique, Joaquín Mosquera, Jorge García et al. · Translational Lung Cancer Research · 2018 · 63 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Tissue factor expressed by microparticles is associated with mortality but not with thrombosis in cancer patients

Carmen Méndez-Hernández, Josune Orbe, Carmen Roncal et al. · Thrombosis and Haemostasis · 2013 · 63 citations · Full text

Medicine, Hematology, Oncology +17